INTRODUCTION
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death globally, with about 800,000 deaths every year.
[1] Unfortunately, considerable number of patients are diagnosed at advanced stage unsuitable for surgery or local treatment with poor prognosis and a median overall survival (OS) of about 6 months. Molecular targeted therapies have demonstrated promising efficacy in the management of cancer. Sorafenib improves survival with median OS rate of 6.5-10.7 months, [2] with significant benefit in time to progression, despite the absence of objective response. Numerous trials are ongoing in search for other molecular agents that are more effective than sorafenib, or combinations of therapy that might improve response and survival rates in patients with advanced HCC. Results of trials with lenvatinib as first-line or regorafenib as second line treatments are promising.
[3] Radioembolisation is as safe and effective in advanced-stage HCC as first-line or second-line therapy. [4] In addition, the use of immunotherapy in clinical trials demonstrated promising results. [5] This manuscript reviews the current treatments and ongoing research for therapy of advanced HCC.
In the BRIDGE study that included data for 18,031 patients with HCC from 42 sites in 14 countries in Asia, Europe and North America, more than 50% of cases were diagnosed in advanced and terminal stages. [7] Whereas 12% of HCC patients in Japan and 17% in Taiwan present in advanced stage HCC (BCLC stage C) and only 1-2% in terminal stage (BCLC D), between 50% and 60% of HCC patients in North America, Europe, China and South Korea present in BCLC stages C and D. [ 
7]
The proportion of HCC patients presenting in advanced stages is even larger in limited resource countries. A study that included 2,566 HCC patients from 21 tertiary referral centers in 9 African countries showed that only 23% presented in early and intermediate stages (BCLC A and B), 49% in advanced stage (BCLC C) and 28% in BCLC stage D. The proportion of patients diagnosed with HCC while in advanced or terminal stage was much larger in sub-Saharan countries, with 95% of the patients diagnosed in BCLC stages C and D, and 97% of 1,315 patients with HCC did not receive HCC specific therapy because of advanced stage and unavailability of therapy. [8] This highlights the importance of developing effective therapies for advanced HCC, and that these therapies should be made available and affordable in limited resource countries where most patients present in advanced stage (especially sub-Saharan Africa). This also emphasizes the importance of screening programs for detection of HCC in early treatable stages.
SYSTEMIC THERAPIES

Molecular targeted therapy
A d v a n c e d H C C h a s e x p e r i e n c e d t h e m o s t relevant advancements in research in HCC lately. Hepatocarcinogenesis is associated with genetic and epigenetic alterations that eventually lead to an alteration in the molecular pathways, leading to uncontrolled growth of the hepatocytes. 
Sorafenib
Sorafenib inhibits the serine-threonine kinases Raf-1 and B-Raf and the activity of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3 and platelet-derived growth factor receptor β (PDGFR-β). Also it induces down-regulation of anti-apoptotic proteins, leading to significant enhancement of the cytotoxicity of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) to HCC cells. [10] Sorafenib improves survival compared to placebo, with median OS of 6.5-10.7 months, with significant benefit in time to progression (TTP). Many molecular agents have been studied, but only the sorafenib showed efficacy in terms of OS and TTP, based on results of two phase III, randomized controlled studies [2, 11] and confirmed in other clinical trials comparing sorafenib to other molecules, [12] [13] [14] [15] [16] as well as in real life clinical practice. [17, 18] Despite the approval of sorafenib in advanced-stage HCC, several issues remain not known. An important concern is to identify patients who will most probably benefit from sorafenib, to avoid unnecessary toxicity in patients who will not. Several markers at baseline or during treatment, as vascular endothelial growth factor, angiopoietin-2, hepatocyte growing factor, c-Kit or alfafeto-protein (AFP) have been shown to predict OS, but not response to sorafenib in patients with advanced HCC. [19] Several reports showed that the development of some adverse events as dermatological adverse events, [20] [21] [22] diarrhea, [23] or arterial hypertension [24] are associated with favorable outcomes. Patients who develop early dermatological adverse events within the first 2 months after starting sorafenib experienced a longer median OS, comparing to those who did not develop this adverse event (18.2 vs. 10.1 months, respectively). [20] Hence, it is mandatory to closely follow the patients and to adjust the dose if needed to avoid unnecessary interruption of the drug in a probably responding patient.
Using sorafenib in patients with Child-Pugh B cirrhosis is challenging. Sorafenib was effective in ChildPugh class B patients as class A patients in terms of progression free survival (PFS), but with lower OS. The median OS was 5.5 months for Child class B patients compared to 11.3 months for Child A patients.
[25] The prospective GIDEON trial confirmed that the median OS was shorter in Child-Pugh class B patients, 5.2 months compared to 13.6 months in Child A, although the TTP and the incidence of adverse events of sorafenib was similar across subgroups, Child-Pugh class B patients experienced more serious adverse events. The liver dysfunction in advanced cirrhosis may impair the effect of sorafenib on tumor progression and interfere with possible survival improvement.
[18]
Eventually 60-70% of patients with advanced HCC progress on sorafenib. The pattern of progression on sorafenib has been identified as a predictor of postprogression survival. [26, 27] The development of new extra-hepatic lesion, vascular invasion, and worsening performance status on therapy were associated with the poorest prognosis.
For patients in advanced-stage who progress on or cannot tolerate sorafenib, management options are limited, and a large unmet need still exists. However, results of trials with lenvatinib as first line therapy [28] and regorafenib [29] and immunotherapy as effective second line treatments are promising.
Other molecular targeted agents
First-line therapy Sorafenib remains the only approved first line therapy with advanced-stage (BCLC-C) HCC. None of the other targeted agents: the anti-angiogenic tyrosine kinase inhibitors (TKI) sunitinib, [12] linifanib, [15] brivanib, [13] dovitinib [16] or the combination of sorafenib with erlotinib [14] were found superior compared to sorafenib in phase II and III trials as first line therapies in patients with advanced HCC, and none have exceeded the benefits of sorafenib [ Figure 1 , Supplementary Table 1] .
Lenvatinib, on the other hand, is showing promising results as first line therapy in advanced HCC.
[3]
Lenvatinib is an oral TKI that targets VEGFR1-3, fibroblast growth factor receptor (FGFR)1-4, rearranged during transfection (RET), receptor tyrosine kinase (KIT), and PDGFR and is approved for radioactive iodine-refractory thyroid cancer. A multicenter, openlabel, phase I/II study of lenvatinib, including 46 patients with advanced HCC. Tumor response and stable disease were found in 37% and 45.7%, respectively, with median TTP of 12.8 months and median OS of 18.7 months. The most common adverse events observed with lenvatinib were hypertension, diarrhea, anorexia, weight loss, and fatigue. [30] Lenvatinib was investigated as first line therapy compared to sorafenib in a multicenter, randomized, open-label, phase III trial that included 954 patients with intermediate or advanced stage HCC. The OS with lenvatinib was non-inferior to sorafenib, and PFS, TTP, and objective response rate (ORR) significantly improved with lenvatinib (NCT01761266).
[31] Lenvatinib thus is the first agent to show results that are equal or better than sorafenib in advanced stage HCC, and might become an alternative to sorafenib as first line treatment. Figure 2 shows OS of second line therapies compared to sorafenib.
Second-line therapy
[29,32-34] Regorafenib, a multi-kinase inhibitor of VEGFR1-3, tyrosine kinase with immunoglobulinlike and EGF-like domains 2 (TIE2), PDGFRβ, FGFR, KIT, RET, rapidly accelerated fibrosarcoma (RAF), is approved for metastatic colorectal cancer and advanced GI stroma tumors. [35, 36] It is the first agent to provide survival benefit after failure of sorafenib in a phase III trial and has recently been approved as second line therapy for HCC. The study included 573 patients who had progressed on sorafenib and it improved OS with a hazard ratio of 0.63 (P < 0.0001); the median OS was 10.6 months for regorafenib vs. 7.8 months for placebo and the disease control rate (DCR) was 65.2% vs. 36.1% (P < 0.001).
[29]
Ongoing studies are evaluating the efficacies [tyrosineprotein kinase Met or hepatocyte growth factor receptor (HGFR)] (c-MET) inhibitors in advanced HCC. A multicenter, randomized, placebo-controlled phase II trial evaluating tivantinib, a selective c-MET inhibitor, included patients with advanced HCC [12] 2013 Johnson et al., [13] 2013 Zhu et al., [14] 2015 Cainap et al., [15] 2015 Cheng et al., [16] 2016 SUN1170 BRISK-FL SEARCH LIGHT 7.9 9.5 9.9 9.5 8. Patients with high c-met expression showed better OS, and prolonged TTP on tivantinib (OS was 7.2 vs. 3.8 months, P = 0.01), and the DCR increased to 50%.
[37] A phase III trial testing tivantinib as second line treatment is ongoing based on better outcome observed in patients with high c-met expression (NCT01755767). Other c-MET inhibitors as foretinib, tepotinib, capmatinib, golvantinib and emibetuzumab are also under investigations.
Ramucirumab, an anti VEGFR monoclonal antibody approved as 2nd line treatment for advanced gastric adenocarcinoma and metastatic lung cancer, was evaluated vs. placebo in a phase III trial as second line treatment in patients with HCC who progressed or were intolerant to sorafenib (REACH study). It demonstrated significant improvement in OS and DCR.
[32] Subgroup analysis showed the survival benefit was limited to patients with baseline AFP ≥ 400 ng/mL (median OS 7.8 months with ramucirumab vs. 4.2 months in the placebo group).
[38] Patients Child-Turcotte-Pugh (CTP) score 5 had better overall response to treatment than patients with CTP scores 6-8, and among those with elevated AFP ≥ 400 ng/mL, improvement with therapy was limited to patients with CTP score 5 and 6 and not in patients with CTP score 7-8 (who experienced higher incident of treatment related grade 3 or higher adverse events).
[39] The phase III REACH-2 trial will evaluate ramucirumab as second-line therapy in patients with advanced HCC and elevated AFP (NCT02435433).
Mammalian target for rapamycin (mTOR) inhibitors in phase I/II studies showed activity in patients with advanced or recurrent HCC.
[40] However, in a phase III study (EVOLVE-1) everolimus did not improve OS in patients with advanced HCC who had failed or were intolerant to sorafenib (median OS, 7.6 months with everolimus, 7.3 months with placebo; HR 1.05; 95% CI 0.86-1.27; P < 0.68).
[33]
Axitinib, a potent and selective inhibitor of VEGFRs 1-3, was investigated as second-line therapy for HCC in a randomized phase II study compared to placebo. Longer PFS (P = 0.004) and TTP (P = 0.006) was observed in patients treated with axitinib compared to placebo. However, no improvement in OS was detected.
[41]
Apatinib, a selective VEGFR-2 tyrosine kinase inhibitor, in a multicenter, randomized, open-label, phase II trial showed potential survival benefit in patients with advanced stage HCC with Child-Pugh class A liver function at either 850 mg/qd or 750 mg/qd. Apatinib was well tolerated and the main AE were elevated aminotransferases, thrombocytopenia, leukocytopenia, hyperbilirubinemia, hypertension, hand-foot syndrome and fatigue. [42] Apatinib is being evaluated as second line therapy in patients with advanced HCC who have progressed on, or were intolerant to, sorafenib (NCT027720290), and other anti-angiogenic agents are in very early-stages of development [Supplementary Table 2 ].
Combination of different molecular targeted therapies
Inhibition of a single signaling pathway may induce feedback activation of other pathways, hence, combination of different molecularly targeted agents possibly induces synergistic beneficial activity.
[43]
Molecular targeted agents other than sorafenib, used in combination or with sorafenib, are being 9.4
Overall survival (months)
Brivanib
Placebo Everolimus Placebo Ramucirumab Placebo Regorafenib Placebo Llovet et al., [34] 2013 Zhu et al., [33] 2014 Zhu et al., [32] 2015 Bruix et al., [29] In a phase III study, the combination of sorafenib and the EGFR-TKI erlotinib in advanced HCC (SEARCH study) did not significantly improve survival over sorafenib alone. [14] Similarly, the combination of the mTOR inhibitor everolimus with sorafenib did not improve the efficacy of sorafenib in patients with unresectable or metastatic HCC.
[44]
Refametinib, an oral mitogen-activated protein kinase (MEK), or mitogen-activated protein kinase (MAPK)/ ERK kinase] inhibitor, combined with sorafenib, improved survival in patients with advanced stage HCC (DCR: 43%, TTP: 122 days, OS: 290 days) with patients with rat sarcoma (RAS) mutations experiencing the best clinical response. However, grades 3 and 4 adverse events were reported in about 80% of cases.
[45] An ongoing trial is evaluating the combination in patients with unresectable or metastatic HCC with RAS mutation (NCT01915602).
Clinical trials of sorafenib in combination with the transforming growth factor receptor beta (TGF-β) inhibitor galunisertib (LY2157299), the mTOR inhibitor temsirolimus, and the histone deacetylase (HDAC) inhibitors vorinostat and resminostat are currently ongoing.
Immune therapy for HCC
Programmed cell death ligand 1 (PDL-1) are expressed on HCC tumor cells. These interact with PD-1 receptors on activated T cells, leading to their inactivation, thus enhancing tumor-cell survival. Blocking the PDL-1-PD-1 receptor interaction increases tumor necrosis. [46] Nivolumab is a fully human IgG4 monoclonal antibody inhibitor of the programmed death-1 (PD-1) receptor that restores T-cell-mediated antitumor activity. Treatment with nivolumab has extended survival in multiple tumor types, and it is approved for metastatic melanoma, metastatic non-small cell lung cancer, advanced renal cell carcinoma, Hodgkin lymphoma, and recurrent or metastatic squamous cell carcinoma of the head and neck. Nivolumab was evaluated in a multiple ascendingdose, phase I/II study in patients with advanced-stage HCC, refusing, intolerant, or progressing on sorafenib with preserved liver function (CTP score up to B7) (Checkmate-040 trial).
[48] Patients received intravenous nivolumab 0.1-10 mg/kg every 2 weeks for up to 2 years, and demonstrated 72% OS rate at 6 months with durable responses across all dose levels and HCC cohorts (ORR:15%, DCR: 65%), with manageable AE profile. These responses were observed regardless of viral hepatitis infection status. In the expansion phase, nivolumab was well tolerated in patients with HBV and HCV related HCC.
[48] OS rates for all patients at 6 and 9 months were 82.5% and 70.8%, respectively. Disease stabilization was observed in patients who previously progressed on sorafenib, 91 of 204 patients (45%) had reduction in tumor burden and 45 (22%) had ≥ 30% reduction in tumor burden compared to baseline.
[48]
A phase III trial evaluating nivolumab vs. sorafenib as first-line treatment in patients with advanced HCC is ongoing (Checkmate-459, NCT02576509).
Cytotoxic-T-lymphocyte-antigen (CTLA)-4 blockade could be an efficient alternative in advanced HCC. In a phase II study, the CTLA-4 inhibitor tremelimumab showed partial response rate 17.6%, DCR 76%, TTP 6.5 months.
[49] However, 45% of patients experienced grade-3 aspartate aminotransferase and alanine aminotransferase elevations. Studies exploring combinations of these agents in a randomized, secondline setting are ongoing. A phase II study is currently evaluating the PD-L1 inhibitor dur valumab and tremelimumab alone or in combination for patients with unresectable HCC who progressed on, are intolerant to, or refused treatment with sorafenib (NCT02519348).
Systemic chemotherapy
Cy totoxic agents as 5 -f luorouracil, cisplatin, doxorubicin, gemcitabine, capecitabin, epirubicin or combined regimens showed a low response rate (< 10%) with slight improvements in OS.
[50,51] Cisplatin, interferon, doxorubicin, and fluorouracil (PIAF) in combination showed favorable results in a phase II study. In a phase III study, PIAF combination compared to doxorubicin alone demonstrated no significant difference in OS (8.67 vs. 6.83 months) or in ORR (20.9% vs. 10.5%).
[51] Patients treated with the PIAF regimen experienced higher rate of myelotoxicity compared with doxorubicin.
The lower effect of doxorubicin in HCC is assumed to result from multidrug resistance (MDR) mechanisms. Doxor ubicin -Transdr ug (DT), a nano -par ticle formulation of doxorubicin, has been shown to enter HCC cells by diffusion, by passing the MDR proteins, and demonstrated higher intracellular concentration and effectiveness than doxorubicin.
[52] A phase III multicenter, randomized, controlled trial comparing the efficacy and safety of IV infusions of doxorubicintransdrug in patients with advanced HCC after failure or intolerance to sorafenib (ReLive Study) is ongoing (NCT01655693).
S-1, an oral mixture of tegafur, gimeracil and oteracil, that increases the effect of 5-fluorouracil through increasing its serum concentration while decreasing its gastrointestinal effects, was evaluated as second line therapy in a phase III trial in patients with advanced HCC refractory to sorafenib (S-CUBE). OS was not different from placebo, but PFS was better (80 vs. 42 days).
[53]
In a phase III study, 371 patients with advanced HCC were randomly assigned to receive either FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) or doxorubicin (EACH trial). OS was higher in patients who received FOLFOX4 compared to doxorubicin (6.4 vs. 4.97 months, P = 0.07) and reached statistical significance after extension of follow up 7 more months (P = 0.04). FOLFOX4 treatment prolonged the median PFS in comparison to doxorubicin (2.93 vs. 1.77 months, P < 0.001), the response rate was 8.15% vs. 2.67% (P = 0.02), and the DCR was 31.55% vs. 52.17% (P < 0.0001) respectively.
[54] FOLFOX4 was well tolerated, although the incidence of neutropenia and neurotoxicity was slightly higher in the FOLFOX4 group.
Oxaliplatin (OXA)-based chemotherapy may be an effective first line treatment for patients with advanced HCC. In a meta-analysis [55] that included 13 studies, 6 studies on gemcitabine, 6 studies on 5-flurouracil or capecitabine and 1 study on doxorubicin in addition to OXA, the PFS was 3.3 and 4 months in capecitabinebased studies and OXA-based studies, respectively. OS was 6.47 months in capecitabine-based studies compared to 11 months in OXA-based studies.
[56]
Combination of sorafenib with systemic chemotherapy
Combination of sorafenib with doxorubicin, [5 7 ] octreotide, [58] 5 -fluorouracil, [59] tegafur/uracil, [60] cisplatin and gemcitabine, [61] gemcitabine/oxaliplatin (GEMOX), [62, 63] and capecitabine/oxaliplatin (SECOX) [64] have been investigated [Supplementary On the other hand, a phase III randomized study of sorafenib plus doxorubicin compared to sorafenib (CALGB 80802) showed higher toxicity for the combination without improvement in OS or PFS.
[65]
The phase III SILIUS trial included 210 patients with advanced HCC, and compared sorafenib to sorafenib in combination with low dose cisplatin/fluorouracil hepatic arterial infusion chemotherapy (HAIC). OS was equal in both arms (11.8 months). However, sorafenib plus HAIC significantly improved OS in the subset of patients with major portal-vein invasion (11.4 months vs. 6.5 months).
[66]
LOCOREGIONAL THERAPY
The presence of por tal vein thrombosis (PV T) is a relative contraindication for trans-ar terial chemo-embolization (TACE) in most international guidelines, [6, 67, 68] TACE may be recommended for HCC patients with vascular invasion if radiologic portal invasion is distal to, or in the second-order branches of, the portal vein (Vp1 or Vp2).
[ 69, 70] Real life studies have confirmed the safety and efficacy of TACE in patients with PVT.
[71]
Combination of targeted therapy with locoregional therapy
Several studies compared sorafenib plus TACE to sorafenib or TACE [72] [73] [74] [75] [76] [77] [78] [Supplementary Table 4] . A meta-analysis of sorafenib in combination with TACE that included data of 1,254 patients found that the combination improved OS and TTP in advanced HCC, but not PFS, with higher rate of severe adverse reaction in the combination group.
[79] This combination is being further evaluated in phase III study (STAH trial, NCT01829035) to evaluate combined sorafenib with conventional TACE vs. sorafenib in patients with TACE-refractory and advanced-stage HCC.
Randomized, controlled studies to evaluate the efficacy and safety of sorafenib combined with TACE in advanced HCC patients compared with sorafenib alone (SELECT) (NCT01906216) or TACE alone (NCT02150317) are ongoing. The safety and efficacy of superselective drug-eluting chemoembolization with hepasphere in patients with unresectable advanced HCC is under investigation (SUPER-China, NCT02743065).
A phase II randomized controlled trial (RCT) conducted to explore the efficacy of sorafenib and TACE in advanced HCC patients with major portal vein invasion (NCT01480817) has been terminated and the results are awaited. Combination of TACE with apatinib (NCT03066557) or axitinib (NCT01352728) in patients with advanced HCC are under investigation. Also, comparing TACE plus sunitinib against TACE plus placebo (SATURNE) (NCT01164202) is ongoing.
Hepatic arterial infusion chemotherapy
The Japanese Society of Hepatology and the Korean National Cancer Center both recommend hepatic ar terial infusion chemotherapy (HAIC) in their guidelines for management of patients with advanced HCC and vascular invasion. In a single-center study in Japan, the HAIC using 5-fluorouracil and pegylated interferon α2b was investigated compared to sorafenib for treatment of advanced HCC. The early ORR was higher in the HAIC group than in the sorafenib group (71.4% vs. 10.5%, P < 0.01). The 18-month survival rate was 55.6% vs. 16.2%, P = 0.03 for the HAIC and sorafenib groups respectively.
[82]
A multi-center study that included 110 patients with advanced HCC found that HAIC using cisplatin and 5-fluorouracil with or without epirubicin, demonstrated higher treatment response rate (24% vs. 13.3%) and a better median OS (7.1 vs. 5.5 months) compared to sorafenib.
[83] A RCT is recruiting to elucidate the efficacy of HAIC of FOLFOX compared to sorafenib in treatment of advanced HCC (NCT02774187). A phase III randomized open label clinical trial to investigate the efficacy and safety of HAIC (using FOLFOX) compared with TACE in patients with HCC with major portal venous tumor thrombus is recruiting (NCT02856126).
The efficacy and safety of HAIC with cisplatin and 5-fluorouracil in patients who have progressed or were intolerant to sorafenib with non-metastatic HCC is being evaluated further, stratified by expression of biomarker predicting therapeutic response is ongoing (the SHINE study, NCT02967887).
Radioembolisation
Trans-arterial radio-embolization (TARE) using Yttrium-90 spheres is well tolerated with survival rates reported similar to TACE with fewer side effects, better response rate and longer time to progression. TARE is as safe and ef fective as sorafenib in advanced-stage HCC.
[4,87-90] The median survival with TARE was 13.8 months compared to 10 months with sorafenib (P > 0.05), and complete response was only observed in 6.3% of patients in the TARE group. TARE alone or combined with sorafenib vs. sorafenib in BCLC stage B and C patients are under evaluation (NCT02288507). In a pilot study, sorafenib for 6-8 weeks before Yttrium-90 treatment for patients with unresectable HCC was safe and tolerable. The DCR was 72.4% and tumor necrosis was observed in 82.8% of patients.
[92]
A phase III RCT of Selective Internal Radiation Therapy (SIRT) versus sorafenib in advanced HCC (SIRveNIB) is ongoing (NCT01135056). A study evaluating the monoclonal antibody to PD-1 receptor nivolumab in combination with TARE is under way (NCT02837029). RCTs are ongoing to define the role of TARE as firstline or second-line therapy in advanced HCC.
CONCLUSION
Sorafenib is still the only approved front-line therapy, and several needs are still unmet and need to be addressed: the combination of local with systemic therapies, the optimal timing of molecular targeted agents in relation to loco-regional treatment, the combinations of systemic targeted therapies, and second-line therapies. Results of recent trials point to several promising therapeutic options: lenvatinib as front-line therapy, and regorafenib and nivolumab as second-line therapy. Several other molecules and combinations are in early stages of development, and more effective therapies will evolve over the next few years. However, improving screening and early detection, and improving access to therapy in limited resource settings are as important in improving global outcome of HCC.
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